BioInfra Co., Ltd. (KOSDAQ:199730)

BioInfra Revenue

BioInfra had revenue of 8.50B KRW in the quarter ending June 30, 2026, with 39.74% growth. This brings the company's total for the last twelve months to 25.62B, up 4.69% year-over-year. In the year 2025, BioInfra had annual revenue of 23.15B, down -2.87%. That makes BioInfra the 34,002nd largest company in the world by revenue and 2,174th in South Korea.

• Revenue (ttm): 25.62B
• Revenue Growth: +4.69%
• P/S Ratio: 0.33
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 8.52B

Revenue Chart

Chart

Chart

Revenue by Segment

• Phase 1 Clinical Trial 12.46B 52.3%
• Bioequivalence Testing 9.76B 41.0%
• Clinical / Non-clinical Sample Analysis 1.19B 5.0%
• Sample Analysis for Not Licensing Purposes, etc. 325.77M 1.4%
• Other 36.94M 0.2%
• Non-approved Clinical Trials 34.71M 0.1%
• Clinical Trials for Approval 22.01M 0.1%

Fiscal year ended Dec 31, 2024 See the full BioInfra breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	23.15B	-685.20M	-2.87%
Dec 31, 2024	23.83B	-6.30B	-20.90%
Dec 31, 2023	30.13B	-5.30B	-14.96%
Dec 31, 2022	35.43B	4.87B	15.94%
Dec 31, 2021	30.56B	10.95B	55.82%

Data Source: S&P Global Market Intelligence Last updated: Jul 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 22, 2026

Data Sources Report a data error